Search

Eva Guinan Phones & Addresses

  • 34 Ridge Ave, Newton Center, MA 02459
  • Newton, MA
  • Boston, MA
  • Lowell, MA

Work

Company: Boston Office Address: 450 Brookline Ave, Boston, MA 02215 Phones: (617) 632-3000

Education

School / High School: Harvard Medical School 1980

Languages

English

Awards

Healthgrades Honor Roll

Ranks

Certificate: Pediatric Oncology & Pediatric Hematology, 1998

Emails

e***n@yahoo.com

Specialities

Pediatric Hematology & Oncology

Professional Records

Medicine Doctors

Eva Guinan Photo 1

Dr. Eva C Guinan, Boston MA - MD (Doctor of Medicine)

View page
Specialties:
Pediatric Hematology & Oncology
Address:
Boston Office
450 Brookline Ave, Boston, MA 02215
(617) 632-3000 (Phone)
Certifications:
Pediatric Oncology & Pediatric Hematology, 1998
Pediatrics, 1986
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
Boston Office
450 Brookline Ave, Boston, MA 02215

Brigham and Women's Hospital
75 Francis Street, Boston, MA 02115

Massachusetts General Hospital
55 Fruit Street, Boston, MA 02114

North Shore Medical Center - Salem Hospital
81 Highland Avenue, Salem, MA 01970
Education:
Medical School
Harvard Medical School
Graduated: 1980
Medical School
Children's Hospital
Graduated: 1980
Medical School
Dana Farber Cancer Institute
Graduated: 1980
Eva Guinan Photo 2

Eva C. Guinan

View page
Specialties:
Pediatric Hematology-Oncology
Work:
Dana-Farber Cancer Institute Center For Neurology-Oncology
450 Brookline Ave FL 10, Boston, MA 02215
(617) 632-6633 (phone), (617) 632-4773 (fax)
Education:
Medical School
Harvard Medical School
Graduated: 1980
Languages:
Chinese
English
French
Spanish
Description:
Dr. Guinan graduated from the Harvard Medical School in 1980. She works in Boston, MA and specializes in Pediatric Hematology-Oncology. Dr. Guinan is affiliated with Boston Childrens Hospital, Brigham & Womens Hospital and MassGeneral For Children At North Shore Medical Center.
Eva Guinan Photo 3

Eva Catharina Guinan, Boston MA

View page
Specialties:
Pediatrics
Pediatric Hematology-Oncology
Hematology & Oncology
Work:
Dana-Farber Cancer Institute
450 Brookline Ave, Boston, MA 02215
Dana-Farber Cancer Institute
44 Binney St, Boston, MA 02115
Children's Hospital
300 Longwood Ave, Boston, MA 02115
Education:
Harvard University(1980)

Business Records

Name / Title
Company / Classification
Phones & Addresses
Eva Catharina Guinan
Eva Guinan MD
Pediatric Oncologist · Pediatrician · Internist
44 Binney St, Boston, MA 02115
(617) 632-4932

Publications

Us Patents

Rantes Levels As A Diagnostic And Therapeutic For Acute Graft Versus Host Disease

View page
US Patent:
20120238460, Sep 20, 2012
Filed:
Nov 10, 2008
Appl. No.:
12/739976
Inventors:
Ofer Levy - Jamaica Plain MA, US
Eva Guinan - Newton MA, US
Eugenie Suter - Chicago IL, US
Assignee:
DANA-FARBER CANCER INSTITUTE, INC. - Boston MA
CHILDREN'S MEDICAL CENTER CORPORATION - Boston MA
International Classification:
C40B 30/04
US Classification:
506 9
Abstract:
Disclosed herein are methods for determining the likelihood of a subject to develop Acute graft versus host disease (aGVHD) upon receiving myeloablative allogeneic hematopoietic stem cell transplantation (HSCT). One such method comprises assaying for baseline plasma concentration of RANTES in a sample obtained from the subject, and comparing the baseline plasma concentration of RANTES to a predetermined level. The method may further comprise assaying for day 7 plasma concentration of RANTES in sample obtained from the subject, and comparing the day 7 plasma concentration of RANTES to a predetermined level. Another such method comprises assaying for day 7 plasma concentration of RANTES in a sample obtained from the subject, and comparing the day 7 plasma concentration of RANTES to a predetermined level. Another such method comprises assaying for donor plasma concentration of RANTES in a sample obtained from a donor of the hemtopoietic stem cells, and comparing the donor plasma concentration of RANTES to a predetermined level, wherein a donor plasma concentration of RANTES less than the predetermined level indicates a likelihood of the subject to develop aGVHD upon receiving myeloablative allogeneic HSCT from that donor. Other methods include assaying for day 0, or for day 7, plasma concentration of MCP-1 in a sample obtained from the subject, and comparing the day 0 or day 7, plasma concentration of MCP-1 to a predetermined level.

Bpi And Its Congeners As Radiation Mitigators And Radiation Protectors

View page
US Patent:
20140142024, May 22, 2014
Filed:
Apr 5, 2012
Appl. No.:
14/009201
Inventors:
Eva Guinan - Newton MA, US
Ofer Levy - Jamaica Plain MA, US
Assignee:
Children's Medical Center Corporation - Boston MA
Dana-Farber Cancer Institute, Inc. - Boston MA
International Classification:
A61K 38/17
A61K 31/496
US Classification:
514 22
Abstract:
Described herein is a method of mitigating, in a subject (individual), tissue injury resulting from exposure to radiation (accidental/unintentional or intentional, such as therapeutic), chemoradiotherapy, disease, toxin, or drug or biologic mediated therapy.
Eva C Guinan from Newton Center, MA, age ~70 Get Report